#1 Clinical Trials Search in Europe

Pc14586

PC14586, also known as rezatapopt, is an innovative oral medication currently being studied in clinical trials for its potential in treating various types of cancer. This article provides an overview of the ongoing research into PC14586, its mechanism of action, and its potential benefits for patients with specific genetic mutations in their cancer cells.

Table of Contents

What is PC14586?

PC14586, also known by its international nonproprietary name (INN) rezatapopt, is a new cancer drug currently being studied in clinical trials[1]. It is described as a “first-in-class” medication, which means it works in a way that is different from other existing drugs[2]. PC14586 is taken orally as a capsule or tablet[2].

How Does PC14586 Work?

PC14586 is designed to target a specific genetic mutation in cancer cells. It is called a “p53 reactivator” that is selective for the TP53 Y220C mutation[2]. To understand this, let’s break it down:

  • p53: This is a protein in our body that helps prevent cancer by controlling cell growth and division. It’s often called the “guardian of the genome.”
  • TP53: This is the gene that provides instructions for making the p53 protein.
  • Y220C mutation: This is a specific change in the TP53 gene that can lead to cancer.

PC14586 is designed to “reactivate” or restore the normal function of p53 in cancer cells that have this specific Y220C mutation[2]. By doing so, it aims to stop cancer cells from growing and dividing uncontrollably.

What Cancers Can PC14586 Treat?

PC14586 is being studied for the treatment of various types of advanced or metastatic solid tumors (cancers that form solid masses) that have the TP53 Y220C mutation[4]. These include:

  • Ovarian cancer
  • Lung cancer
  • Breast cancer
  • Endometrial cancer (cancer of the lining of the uterus)
  • Colorectal cancer
  • Prostate cancer
  • Head and neck cancer
  • Other solid tumors

It’s important to note that PC14586 is specifically designed for cancers with the TP53 Y220C mutation. This means that before a patient can receive this treatment, their cancer cells would need to be tested for this specific genetic change[4].

Current Research on PC14586

Several clinical trials are currently underway to study PC14586:

  1. Phase 1/2 Trial (PYNNACLE): This study is looking at the safety, how well the drug is tolerated, and how effective it is in patients with advanced solid tumors that have the TP53 Y220C mutation. It’s testing PC14586 both alone and in combination with another cancer drug called pembrolizumab[4].
  2. Absorption, Metabolism, and Excretion Study: This study is examining how PC14586 is processed and eliminated by the body in healthy male volunteers[1].
  3. Food Effect Study: This research is investigating how food affects the way PC14586 is absorbed and processed by the body. It’s also looking at how the drug behaves in Japanese volunteers[2].
  4. Drug Interaction Studies: These studies are examining how PC14586 interacts with other medications, specifically:
    • Acid-reducing agents like rabeprazole and famotidine[3]
    • Itraconazole, an antifungal medication[5]

These studies will help researchers understand how to best use PC14586, what dose to give, and what other medications might affect its effectiveness or safety.

Potential Side Effects

As PC14586 is still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are carefully monitoring for any adverse events (unwanted or harmful effects) that might occur. These could include:

  • Changes in blood tests (hematology and clinical chemistry)
  • Abnormalities in heart rhythm (detected by ECG)
  • Changes in blood pressure
  • Changes in pulse rate
  • Changes in body temperature

It’s important to remember that not all participants will experience side effects, and the benefits of the treatment may outweigh the risks for many patients[4].

Future Directions

The research on PC14586 is still in its early stages, but the results could potentially lead to a new targeted therapy for certain types of cancer. If successful, it could offer hope to patients whose cancers have the specific TP53 Y220C mutation.

Future research may explore:

  • Combining PC14586 with other cancer treatments
  • Using PC14586 in earlier stages of cancer
  • Identifying other genetic mutations that PC14586 might be effective against

As with all new medications, it will take time and more research to fully understand the potential benefits and risks of PC14586. Patients interested in this treatment should discuss it with their oncologist to see if it might be appropriate for their specific situation[4].

Aspect Details
Drug Name PC14586 (rezatapopt)
Drug Type First-in-class, oral, small molecule p53 reactivator
Target TP53 Y220C mutation in solid tumors
Cancer Types Studied Ovarian, lung, breast, endometrial, colorectal, prostate, head and neck cancers
Clinical Trial Phases Phase 1/2
Administration Oral capsules or tablets
Key Objectives Safety, tolerability, pharmacokinetics, efficacy
Combination Studies With pembrolizumab (immunotherapy)
Efficacy Measures Overall Response Rate, Progression-Free Survival, Overall Survival
Safety Monitoring Adverse events, vital signs, ECG, laboratory tests

FAQ

  • What is PC14586 and how does it work? PC14586 (rezatapopt) is a first-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation. It works by targeting and reactivating the p53 protein, which plays a crucial role in suppressing tumor growth.
  • What types of cancer is PC14586 being studied for? PC14586 is being studied for various advanced solid tumors, including ovarian, lung, breast, endometrial, colorectal, prostate, and head and neck cancers. It is specifically targeted at cancers harboring the TP53 Y220C mutation.
  • How is PC14586 administered to patients? PC14586 is administered orally as a capsule or tablet. The dosing schedule and amount may vary depending on the specific clinical trial and treatment phase.
  • What are the main goals of the clinical trials involving PC14586? The main goals of the clinical trials are to assess the safety, tolerability, pharmacokinetics (how the drug moves through the body), and efficacy of PC14586. Researchers are also studying its effects when used alone and in combination with other cancer treatments.
  • Are there any known side effects of PC14586? As PC14586 is still in clinical trials, the full range of potential side effects is not yet known. The trials are closely monitoring for any adverse events, changes in vital signs, ECG abnormalities, and laboratory test results to ensure patient safety.

Ongoing Clinical Trials on Pc14586

  • Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

Glossary

  • p53: A protein that acts as a tumor suppressor, helping to prevent the development and growth of cancer cells.
  • TP53 Y220C mutation: A specific genetic mutation in the TP53 gene that PC14586 is designed to target and reactivate.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Maximum Plasma Concentration (Cmax): The highest concentration of a drug in the blood plasma after administration.
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time, used to assess its effectiveness and potential side effects.
  • Time to Maximum Plasma Concentration (Tmax): The time it takes for a drug to reach its highest concentration in the blood plasma after administration.
  • Half-life (t1/2): The time it takes for the concentration of a drug in the body to decrease by half.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug recommended for further testing in Phase 2 clinical trials based on safety and efficacy data from Phase 1 trials.

References

  1. https://clinicaltrials.gov/study/NCT05523687
  2. https://clinicaltrials.gov/study/NCT05249348
  3. https://clinicaltrials.gov/study/NCT06054464
  4. https://clinicaltrials.eu/trial/study-of-pc14586-for-patients-with-advanced-solid-tumors-with-a-specific-tp53-mutation/
  5. https://clinicaltrials.gov/study/NCT06362642